AACR logo

More articles from Commentary

Countering Breast Cancer's Counterpunch
Brion W. Murray

Molecular Cancer Therapeutics Oct 2019, 18 (10) 1682-1683; DOI: 10.1158/1535-7163.MCT-19-0875
Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy
Yu Shi, Sean Hunter, Tony Hunter

Molecular Cancer Therapeutics Aug 2019, 18 (8) 1337-1340; DOI: 10.1158/1535-7163.MCT-19-0605
Precision Medicine: Progress, Pitfalls, and Promises
Patrick G. Pilié, Patricia M. LoRusso, Timothy A. Yap

Molecular Cancer Therapeutics Dec 2017, 16 (12) 2641-2644; DOI: 10.1158/1535-7163.MCT-17-0904
Mitogen-Activated Protein Kinases Inhibitors: Potential Therapeutic Agents for Cancer Cachexia
Vickie E. Baracos

Molecular Cancer Therapeutics Feb 2017, 16 (2) 263-264; DOI: 10.1158/1535-7163.MCT-16-0753
The Myb–p300 Interaction Is a Novel Molecular Pharmacologic Target
Xi Liu, Kathryn A. Gold, Ethan Dmitrovsky

Molecular Cancer Therapeutics Jun 2015, 14 (6) 1273-1275; DOI: 10.1158/1535-7163.MCT-15-0271
Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor
Craig P. Carden, L. Rhoda Molife, Johann S. de Bono

Molecular Cancer Therapeutics Aug 2009, 8 (8) 2077-2078; DOI: 10.1158/1535-7163.MCT-09-0641
Liposomal delivery as a mechanism to enhance synergism between anticancer drugs
Robert J. Lee

Molecular Cancer Therapeutics Jul 2006, 5 (7) 1639-1640; DOI: 10.1158/1535-7163.MCT-06-C02
Apoptosis and anthracycline cardiotoxicity
Andrew Thorburn, Arthur E. Frankel

Molecular Cancer Therapeutics Feb 2006, 5 (2) 197-199; DOI: 10.1158/1535-7163.MCT-06-CO1
Confirmation and prevention of targeted toxicity by a recombinant fusion toxin
Robert J. Kreitman

Molecular Cancer Therapeutics Dec 2004, 3 (12) 1691-1692;
Small molecule inhibition of hypoxia inducible factor-1α: A viable therapeutic approach?
Kenneth D. Tew

Molecular Cancer Therapeutics Mar 2004, 3 (3) 245-246;

Main menu

User menu

Search

More articles from Commentary

Pages

Articles

Info for

About MCT